Primate model created to study oculocutaneous albinism genes

A pair of gene names — TYR and OCA2 — sit at the centre of most oculocutaneous albinism cases worldwide. Both govern the production of melanin, and mutations in either can reduce or eliminate pigment in the skin, hair, and eyes. Until recently, researchers studying these mutations relied largely on rodent models, which replicate only part of the biology involved.

A study published in Science Partner Journals reports the development of a nonhuman primate model carrying targeted mutations in both the TYR and OCA2 genes. The researchers used gene-editing techniques to introduce the mutations, producing animals that presented with the reduced pigmentation and ocular features associated with oculocutaneous albinism in humans, according to the study.

Why primates matter here

The visual system of nonhuman primates is structurally closer to the human eye than that of mice or rats. The fovea — the small central region of the retina responsible for sharp, detailed vision — is present in primates but absent in most rodents, the study noted. Because foveal development is commonly affected in people with albinism, the researchers argued that a primate model offers a more accurate platform for studying that process.

The study found that animals with the edited mutations displayed characteristics consistent with oculocutaneous albinism type 1 and type 2, the two most prevalent forms of the condition. Pigmentation was visibly reduced across skin and coat, and the researchers reported observable changes in retinal structure, according to the published findings.

The OCA2 gene mutation, in particular, has long been difficult to study in rodents because mice carry a functionally different version of the gene. The primate model, the researchers said, offers a closer genetic and anatomical parallel to human OCA2 cases.

What the model is intended to do

The authors described the model as a tool for preclinical research — a controlled setting in which potential therapies could be evaluated before any human trials. The study identified vision development and nystagmus, the involuntary eye movement common in people with albinism, as two areas where the model may prove particularly useful, according to the paper.

The research was published in Science Partner Journals and indexed on PubMed. Independent peer review of the findings has not yet been widely reported beyond the journal's own process.

For the community, a more anatomically accurate research model means that experimental treatments — whether gene therapies, pharmacological interventions, or developmental supports — can be tested with greater confidence before reaching clinical stages. That step, measured and slow as it is, is where most meaningful change in medical understanding begins.